Update shared on08 Aug 2025
Fair value Increased 2.72%Mirum Pharmaceuticals’ modest target price increase reflects improved consensus revenue growth forecasts, though this is partially offset by a slight expansion in the future P/E multiple, resulting in a marginal upward revision of the fair value to $77.20.
What's in the News
- Mirum Pharmaceuticals raised its 2025 revenue guidance to $490 million to $510 million.
- The company was dropped from the Russell 3000E, Russell 3000E Growth, Russell Microcap, Russell Microcap Growth, and related index benchmarks.
Valuation Changes
Summary of Valuation Changes for Mirum Pharmaceuticals
- The Consensus Analyst Price Target remained effectively unchanged, moving only marginally from $76.20 to $77.20.
- The Consensus Revenue Growth forecasts for Mirum Pharmaceuticals has risen from 21.6% per annum to 22.8% per annum.
- The Future P/E for Mirum Pharmaceuticals has risen slightly from 52.24x to 53.39x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.